STK11 and neoplasm: Additionally, our results provide novel insights into the design of immunotherapeutic strategies for DLBCL and support the genetic reprogramming of Tregs to inhibit Lkb1 or Lkb1-related pathways as an attractive strategy for anti-tumor immunotherapy.